tesa Labtec Announces Successful Completion of FDA Pre-Approval Inspections of Its R&D and Manufacturing Facilities
The German patch and oral thin film maker announces the completion of a Pre-Approval Inspection (PAI) by the US Food and Drug Administration (FDA) in February 2016.
During a total of 7 days of inspection, FDA visited both, the R&D site in Langenfeld as well as the manufacturing facility in Hamburg, Germany. FDA provided feedback with a short list of observations which tesa Labtec takes seriously. At the conclusion of the inspections, the FDA Investigator said that the initial conclusion was to approve the sites for commercial activities. That conclusion must still be reviewed within FDA. The company is responding promptly to the observations which the Investigator raised.
“This FDA inspection demonstrates a significant milestone within our plan to expand our business to the US market.” stated Dr. Ingo Lehrke, Managing Director of tesa Labtec. “The inspection paves the way to the US market for our customers’ transdermal patches and oral thin films and certifies the high quality of our development and manufacturing capabilities. This achievement was made possible through the dedication of our talented staff.” Dr. Lehrke concluded.
The PAI was triggered by a customer’s ANDA filing for a transdermal patch, which is manufactured by tesa and is designated for US distribution.
About tesa Labtec GmbH
tesa Labtec offers the development and manufacture of film shaped dosage forms (CDMO services) like transdermal and topical patches as well as buccal or sublingual films. The business activities comprise formulation development, scale up and manufacture of clinical trial supplies or finished products under full cGMP conditions. Thereby tesa counts on its proprietary technologies Transfilm® , Rapidfilm® and Mucofilm® . tesa Labtec is a wholly owned subsidiary of tesa SE, a member of the Beiersdorf group of companies, and represents the pharmaceutical business in a truly global family of companies.
tesa Labtec GmbH
Director Business Development
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
MA-VERTEX-PHARMA21.2.2018 22:03 | pressemeddelelse
Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis
AZ-UNIVERSAL-LASER21.2.2018 19:02 | pressemeddelelse
Universal Laser Systems® Expands Portfolio of Laser Material Processing Systems with the ULTRA Platform Series
WA-LUXOFT21.2.2018 17:32 | pressemeddelelse
Luxoft One of Six Companies Collaborating with Amazon Web Services to Accelerate Blockchain Adoption
WESTINGHOUSE-ELECTRIC21.2.2018 17:32 | pressemeddelelse
Westinghouse Electric Company to Provide Engineering Support at Vandellós 1 in Partnership with EDF
FL-H.I.G.-CAPITAL21.2.2018 15:04 | pressemeddelelse
H.I.G. Europe Completes a Strategic Investment in Puerto de Indias Group
VA-SAVI-TECHNOLOGY21.2.2018 14:04 | pressemeddelelse
Savi Adds Supply Chain Star Johannes Giloth to Advisory Board
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum